Research record
Imatinib / KIT-context melanoma
If the report shows a KIT alteration, ask whether it is activating/actionable and whether KIT-directed trials or evidence apply.
What this is
If the report shows a KIT alteration, ask whether it is activating/actionable and whether KIT-directed trials or evidence apply.
Why it may come up
- KIT mutation or amplification
- selected acral/mucosal/subtype context
What not to assume
- Avoid mutation-class overgeneralization.
At a glance
Imatinib / KIT-context melanoma
- Type
- Targeted therapy
- Mutation result
- KIT
- Where
- Global
- Evidence status
- In clinical trials
- Last checked
- 2026-05-20
What we know
- NCI PDQ discusses KIT pathogenic variants in cannot be removed by surgery stage III or stage IV melanoma evidence context.
- NCI trial records include imatinib-based KIT melanoma studies.
What is unclear
- Which KIT variants predict benefit must be checked against the exact report and oncology team.
Questions to ask
- Is the KIT alteration activating/actionable?
- Does the trial or evidence match this exact KIT variant?
- Is the melanoma subtype acral, mucosal, or another subtype where KIT is more relevant?